3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 4
1
Phase 2/3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Glioblastoma
1
Drug-Related Side Effects and Adverse Reactions
1
Depression
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anxiety Disorders
1
All Solid Tumors
1
Interventions
pembrolizumab
43
Nivolumab
24
Gemcitabine
23
Cyclophosphamide
22
Paclitaxel
17
Capecitabine
16
fludarabine
15
Ipilimumab
14
aldesleukin
11
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Trastuzumab
10
Cetuximab
10
Bevacizumab
10
Albumin-Bound Paclitaxel
9
fludarabine phosphate
8
Specimen Handling
8
Interleukin-2
8
Fluorouracil
8
Cisplatin
8
Biopsy
8
Radiosurgery
7
Oxaliplatin
7
Irinotecan
7
durvalumab
6
avelumab
6
Temozolomide
6
Pemetrexed
6
Leucovorin
6
Carboplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasm Metastasis
×
Pharmaceutical Preparations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled